Ambiki vs. Fusion: the tape

The better product lost the sale.

Two vendor demos, secret-shopped as the same prospective buyer inside the same two-week window. On a 10-axis buyer-experience rubric, Ambiki showed up with the better-fit, cheaper product and the weaker commercial motion.

This is the evidence layer under the June 1 commercial-motion memo and the June 5 KPI model. Those argued where Ambiki's commercial leverage should be and how I'd measure it, both from the outside, both labeled as hypotheses. This tests them against primary data: where the memo said "here's what I'd want to confirm on a call," this says "here's what the call actually showed."

Two vendor demos run as a prospective buyer: an 8-provider pediatric-speech practice, merging two clinics, commercial + self-pay, telehealth a must-have, October go-live, decision by end of August. Ambiki (Charlotte Rodriguez, Business Development Lead) on July 2; Fusion (Brittany, Account Executive) on July 7.

The headline is uncomfortable and useful: Ambiki showed up with the better-fit, cheaper product and the weaker commercial motion. Fusion showed up with the more mature sale. On a 10-axis buyer-experience rubric, Fusion scored ~4.1/5 and Ambiki ~2.9/5, and the gap is entirely in selling, not software. On several dimensions the buyer cared about (aging report, two-second autosave, no storage cap, Google Calendar sync, RCM assistance at no stated added service fee, generous onboarding seat model, an AI progress tracker), Ambiki was visibly ahead.

On price Ambiki wins, though by less than the call implied: base seats run ~$438/monthfor this practice, and with the buyer's must-have telehealth add-on (+$20/user) and per-claim fees, a realistic all-in lands near $600/month, against Fusion's $1,186/month quoted (public Premier list is ~$812/mo for eight providers before admins, RCM and AI scribe extra). Call it roughly half Fusion's cost, not a third, still a decisive advantage, and the Ambiki rep never once made the math visible.

Three findings matter most, and each maps directly to something the June 1 memo flagged as an open question:

None of these are product problems. They're commercial-motion problems, which is precisely the job the CCO is being hired to fix, and precisely where the June 1 memo and June 5 model already pointed. The rest of this document is the evidence.

One rubric, both reps, 1–5, scored off the transcripts. The point is comparison on fixed axes, not vibes, and to make the "better product, weaker sale" split legible.

Buyer-experience by axis: score out of 5

Ambiki's only axis at or above Fusion is switch-risk mitigation (the PMaaS/onboarding substance), and even that was delivered late and reactively. Every axis where Fusion pulls ahead (positioning, pricing motion, command of the process) is a commercial muscle, not an engineering one.

3.1 Discovery: Fusion diagnosed, Ambiki inventoried

Charlotte's discovery was a short intake: how many therapists, what insurance types, telehealth-only or not, and "are you using an EMR right now." Useful, but it stopped at facts. She didn't ask what the buyer's role was, how the billing decision would actually get made, what the budget frame was, or who else was involved, and she didn't return to any of it until the final two minutes.

Brittany opened the same way but kept going into diagnosis:

and, on billing:

That second question does real work: it establishes the buying situation before pitching a solution, and it let her tailor the entire RCM segment to a buyer mid-merger. This is the difference between an intake and a discovery, and it's the exact "linger on the problem" instinct Kevin's own book argues for. Ambiki's founder wrote the playbook; Ambiki's rep didn't run it.

3.2 Positioning: the missing story, and the missing battlecard

This is the single most important finding, so I want it precise. Across a 42-minute call, Charlotte never used the phrases "Practice Management as a Service," "PMaaS," or "four pillars." She never framed a category, never said "here's what makes us different from an EMR," never said "here's why practices leave Fusion for us." The support-and-service advantage, which is the actual moat and the actual PMaaS story, came out only at minute 37, and only because the buyer asked a support question.

Meanwhile the buyer had handed her a fully-loaded competitive setup: frustration with Fusion's admin controls, "constantly getting hit with price increases," no aging report, and providers "losing documents… so frequently" they'd resorted to copying notes elsewhere. Each is a Fusion weakness Ambiki answers well, and Charlotte didanswer them individually and well (aging report: "very loved by billers"; autosave: "every like two seconds"; storage: "we don't have storage limits"). But she never tied the bow: these aren't four coincidences, they're the reason to switch, and here's the pattern.

Contrast Brittany, who volunteered a competitive teardown of Ambiki without being asked to and while being asked only "how do you compare":

That is a clean, memorable, damaging frame (new, buggy, cheap-because-unfinished), and it will be sitting in this buyer's head at decision time. Ambiki has no equivalent counter-frame, because its rep didn't deploy one.

Since these calls I've built the first cut of exactly that deliverable (the proprietary-features battlecard, with the uniqueness statement as its one-paragraph spine), and the exercise surfaced the real backbone of the "why-Ambiki" story the rep never told: not a feature list anyone can match, but defensible IP.Five of Ambiki's headline tools are trademarked or patent-pending in its own feature inventory: Reconsil™ (patent-pending self-balancing ledger), Tenalog® (transcript-to-note AI), Pacing™ (utilization-optimizing scheduling), and Click Beacon™ / Seamless Swap™ (facilitator-free remote assessment). That's a moat Fusion's "buggy startup" frame can't touch, because it reframes "new" as "proprietary." The raw material for the counter-narrative wasn't only the buyer's Fusion pains; it was Ambiki's own patent-pending IP, and neither made it onto the call.

3.3 Pricing: the biggest unforced error

Charlotte gave the tier structure clearly ($59 Professional, $25 Limited) but stopped there: "after the meeting I'll send you an email… and I can give you a more exact quote." No total, no math, no value frame.

Brittany did the opposite; she quoted live, on screen:

Then de-risked price explicitly: "We never want pricing to be an objective for you."

Here's why Ambiki's deferral is costly. Do the math the buyer would do: seven Professional seats + one Limited = ~$438/month base. Fusion for the same practice: $1,186/monthquoted (public Premier list ≈ $812/mo for eight providers before admins), RCM extra, AI scribe $29/therapist, $10 fax line. Ambiki wins on price by a wide margin, and its rep let that stay invisible while Fusion's rep made her larger number concrete, promotional, and urgent. The one place Ambiki wins outright, it failed to cash in.

But the July 9 pricing-page refresh surfaced something sharper, and it cuts against Ambiki's own rep. Ambiki's published pricing is more à la carte than Charlotte disclosed on the call. Teletherapy, the buyer's stated must-have, is a +$20/user/monthadd-on, not the "integrated" freebie the call implied; Therapy Tools are +$5/user, Tenalog is $1/session, insurance claims are $0.25 each, faxing $0.08/page, SMS reminders $0.05 each. Loaded with the telehealth the buyer explicitly required, the real Ambiki figure is closer to ~$600/month, not $438. So the seller managed to both leave her price advantage unquantified and under-state her own list: quoting the naked $59/$25 while the published structure carries meaningful add-ons. That's not a pricing problem; it's the same packaging-isn't-systematized problem that shows up in the RCM contradiction below. "Price opens the door" was a hypothesis in the June 1 memo; this call shows the door left closed by the seller, not the buyer, and shows the seller didn't have a firm grip on her own price sheet.

The same July 11 pass quantified the value frame the call omitted entirely. The strongest number the rep never reached for isn't the seat-price gap; it's the consolidation math. Ambiki folds billing/RCM, teletherapy, accounting reconciliation, payroll, a therapy-resource library, and SMS/fax into one HIPAA-compliant platform; bought as standalone tools, that stack runs roughly $315–650/month (illustrative industry-typical ranges, not a validated Ambiki savings claim; see the battlecard§2). For a merging two-clinic practice already paying for several of those point tools, "one login, one compliance surface, cancel five subscriptions" is a sharper close than "$59 a seat", and the value-copy gap analysis shows that consolidation story is missing from the website too, not just the call.

3.4 Product knowledge: where a competitive gap peeked through

Charlotte knows the product deeply, but two moments matter. First, on ambient AI scribe:

Fusion's scribe already does ambient listening today (Brittany demoed it live, $29/therapist July promo). Ambiki's is "upcoming," and the rep couldn't confirm its headline capability. That's both a product-maturity gap andan enablement gap: the rep should know the answer cold because it's a direct competitive comparison point. Second, the demo environment fought her (duplicate patient records, "who built this… somebody is assigning sessions to me"), which quietly reinforces exactly the "startup, rough edges" frame Fusion is selling against her.

3.5 Command of the process: Fusion ran a sale, Ambiki ran a demo

Brittany closed like someone with a pipeline to forecast: she asked the decision process ("other stakeholders that need to… take a look"), surfaced that a head therapist would review finalists, restated the timeline (decision August, launch October), attached promo urgency (expires July 31), and booked a specific next touch ("reconnect… the week of the 27th"). That's a mutual action plan.

Charlotte's close was "I'm going to send you all this information along with the pricing" and "we can get you started on the trial… keep in contact through the trial." No date, no decision-process discovery, no stakeholder map, no attempt to multithread proactively beyond offering more demos if asked. The trial was doing the job a sales process should do, which is the June 1 hypothesis confirmed on tape.

The memo's whole value was the questions in its §2. Here's what the tape does to each.

There is no single, enforced source of truth for how the offer is packaged and priced. It's exactly the "one funnel definition both teams sign" discipline the June 5 model §1.4 calls for, applied to messaging instead of metrics.

The call is the sharp end; the demand engine behind it is consistent with what the calls implied. Figures below verified against live pricing/review pages on July 9, 2026.

For the full top-of-funnel teardown (a 4,222-URL content-footprint map, the buyer-intent SERP gaps, review-volume and social benchmarks, and ranked acquisition moves), see the companion Acquisition Channels & SEO. Headline: Ambiki's content engine (≈66% free clinician tools) builds affinity, not pipeline, and it's invisible on the commercial keywords where EMR purchases start.

Ordered by commercial leverage, not effort. Each ties to a KPI already defined in the June 5 KPI tree so the fix is measurable from day one.

Same posture as the memo: these are where I'd start, built so I'd know fast if I were wrong.

Ambiki doesn't need a better product to beat Fusion in this deal; it needs a better sale.

That's the most encouraging possible finding for someone stepping into the CCO seat, because commercial motion is exactly what the role builds, and the raw material (better fit, lower price, a real service moat) is already there and already winning the click. It's losing the conversation, and the conversation is fixable.